News tagged with irinotecan

Related topics: chemotherapy

Geriatric factors can foretell tolerances to chemotherapy

(HealthDay)—For elderly patients with metastatic colorectal cancer (mCRC), scores on the Mini-Mental State Examination (MMSE) and Instrumental Activities of Daily Living (IADL) were predictive of severe toxicity or unexpected ...

Mar 14, 2013
popularity0 comments 0

Zaltrap approved for advanced colorectal cancer

(HealthDay) -- Zaltrap (ziv-afilbercept) has been approved by the U.S. Food and Drug Administration in combination with a FOLFIRI chemotherapy regimen for adults with advanced metastatic (spreading) colorectal cancer, the ...

Aug 04, 2012
popularity0 comments 0

Dose-escalated cetuximab tolerated in colorectal cancer

(HealthDay) -- For patients with irinotecan-refractory metastatic colorectal cancer (CRC), dose escalation of cetuximab is well tolerated and may improve response and disease control rates, but patients experience more grade ...

Jul 05, 2012
popularity0 comments 0

How chemotherapy becomes more effective

Researchers from the University of Zurich have found a cellular brake that protects cancer cells from chemotherapy -- and they demonstrate which medication can be used to render it inoperative. Their study published in the ...

Mar 05, 2012
popularity0 comments 0

Irinotecan

Irinotecan (Camptosar, Pfizer; Campto, Yakult Honsha) is a drug used for the treatment of cancer.

Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1. In chemical terms, it is a semisynthetic analogue of the natural alkaloid camptothecin.

Its main use is in colon cancer, in particular, in combination with other chemotherapy agents. This includes the regimen FOLFIRI, which consists of infusional 5-fluorouracil, leucovorin, and irinotecan.

Irinotecan received accelerated approval by the U.S. Food and Drug Administration (FDA) in 1996 and full approval in 1998. During development, it was known as CPT-11.

This text uses material from Wikipedia, licensed under CC BY-SA

Subscribe to rss feed